Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

Open access

Published version of a preprint

Abstract

CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-wide screens in human cells 1-3 . Whereas some cell types are amenable to genome engineering, genomes of human pluripotent stem cells (hPSCs) have been difficult to engineer, with reduced efficiencies relative to tumour cell lines or mouse embryonic stem cells 3-13 . Here, using hPSC lines with stable integration of Cas9 or transient delivery of Cas9-ribonucleoproteins (RNPs), we achieved an average insertion or deletion (indel) efficiency greater than 80%. This high efficiency of indel generation revealed that double-strand breaks (DSBs) induced by Cas9 are toxic and kill most hPSCs. In previous studies, the toxicity of Cas9 in hPSCs was less apparent because of low transfection efficiency and subsequently low DSB induction 3 . The toxic response to DSBs was P53/TP53-dependent, such that the efficiency of precise genome engineering in hPSCs with a wild-type P53 gene was severely reduced. Our results indicate that Cas9 toxicity creates an obstacle to the high-throughput use of CRISPR/Cas9 for genome engineering and screening in hPSCs. Moreover, as hPSCs can acquire P53 mutations 14 , cell replacement therapies using CRISPR/Cas9-enginereed hPSCs should proceed with caution, and such engineered hPSCs should be monitored for P53 function.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0050-6

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

1 retracted

Show all 61 references

Research works printed but not linked: 5

  1. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). · DOI · Paper page
  2. Wells, M. F. et al. Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection. Stem Cell 19, 703–708 (2016).
  3. Liang, X. et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44–53 (2015). · DOI · Paper page
  4. Chindelevitch, L. et al. Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics 28, 1114–1121 (2012). · DOI
  5. Jaeger, S. et al. Causal network models for predicting compound targets and driving pathways in cancer. J. Biomol. Screen. 19, 791–802 (2014). · DOI

Cited by

See all 1,002

Metadata

Authors
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., Randhawa, R., Kulkarni, T., Yang, Z., McAllister, G., Russ, C., Reece-Hoyes, J., Forrester, W., Hoffman, G. R., Dolmetsch, R., & Kaykas, A.
Affiliations
Blueprint Medicines (United States) (US)
Corresponding author
Kaykas, Ajamete
Venue
Nature Medicine
Published
2018-06-11
Volume
24
Issue
7
Pages
939-946
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2807198924
Cited by
978
References
61
Citations by year
2026: 67 · 2025: 74 · 2024: 109 · 2023: 108 · 2022: 126 · 2021: 129 · 2020: 144 · 2019: 144 · 2018: 76
FWCI
43.83
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.springer.com/tdm (tdm)
Locations
  • Nature Medicine (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novartis Institutes for BioMedical Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords
p53, CRISPR/Cas9, human pluripotent stem cells, genome editing efficiency, DNA damage response, TP53 mutation, cell replacement therapy, genome-wide screen
MeSH terms
CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Genetic Engineering, Humans, RNA, Messenger, Transcription, Genetic, Tumor Suppressor Protein p53, Gene Deletion, fas Receptor, Pluripotent Stem Cells, Cyclin-Dependent Kinase Inhibitor p21, DNA Breaks, Double-Stranded, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. https://app.cochat.ai/papers/10.1038/s41591-018-0050-6
The paper
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., Randhawa, R., Kulkarni, T., Yang, Z., McAllister, G., Russ, C., Reece-Hoyes, J., Forrester, W., Hoffman, G. R., Dolmetsch, R., & Kaykas, A. (2018). p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nature Medicine. https://doi.org/10.1038/s41591-018-0050-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.